Feed aggregator

Opinion: Ozempic’s Pros, Cons and Correct Use Cases

Biospace news - Fri, 10/13/2023 - 02:00
Opinion: Ozempic’s Pros, Cons and Correct Use Cases 10/13/2023

Opinion: Akero’s Three-Step Plan to Win Back Investors

Biospace news - Fri, 10/13/2023 - 02:00
Opinion: Akero’s Three-Step Plan to Win Back Investors 10/13/2023

Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially ...

Biospace news - Wed, 10/11/2023 - 02:00
Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially ... 11/10/2023

AstraZeneca’s Imfinzi, Chemo Combo Meets Endpoint in Phase III Liver Cancer

Biospace news - Wed, 10/11/2023 - 02:00
AstraZeneca’s Imfinzi, Chemo Combo Meets Endpoint in Phase III Liver Cancer 11/10/2023

Novo Pumps $6B into Manufacturing to Help Meet Sky-High Wegovy Demand

Biospace news - Wed, 10/11/2023 - 02:00
Novo Pumps $6B into Manufacturing to Help Meet Sky-High Wegovy Demand 11/10/2023

Takeda Wins First FDA Approval for Ultra-Rare Blood Clotting Disease

Biospace news - Wed, 10/11/2023 - 02:00
Takeda Wins First FDA Approval for Ultra-Rare Blood Clotting Disease 11/10/2023

Valneva Gets FDA’s First Chikungunya Vaccine Approval After Delay

Biospace news - Wed, 10/11/2023 - 02:00
Valneva Gets FDA’s First Chikungunya Vaccine Approval After Delay 11/10/2023

Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry

Biospace news - Wed, 10/11/2023 - 02:00
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry 11/10/2023

Merck Touts Keytruda Phase III NSCLC Survival Data Ahead of FDA Decision

Biospace news - Tue, 10/10/2023 - 02:00
Merck Touts Keytruda Phase III NSCLC Survival Data Ahead of FDA Decision 10/10/2023

Akero’s Phase IIb NASH Data Disappoints, Sends Stock Plummeting

Biospace news - Tue, 10/10/2023 - 02:00
Akero’s Phase IIb NASH Data Disappoints, Sends Stock Plummeting 10/10/2023

Newron's Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III

Biospace news - Tue, 10/10/2023 - 02:00
Newron's Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III 10/10/2023

Xenon’s Add-On Epilepsy Treatment Shows Promising Phase IIb Efficacy, Safety

Biospace news - Tue, 10/10/2023 - 02:00
Xenon’s Add-On Epilepsy Treatment Shows Promising Phase IIb Efficacy, Safety 10/10/2023

FDA Blocks Alnylam’s Bid to Expand Onpattro Label

Biospace news - Mon, 10/09/2023 - 02:00
FDA Blocks Alnylam’s Bid to Expand Onpattro Label 10/9/2023

BMS Buys Mirati for $4.8B to Boost Cancer Business

Biospace news - Mon, 10/09/2023 - 02:00
BMS Buys Mirati for $4.8B to Boost Cancer Business 10/9/2023

Novartis Wins FDA Approval for Intravenous Cosentyx Formulation

Biospace news - Mon, 10/09/2023 - 02:00
Novartis Wins FDA Approval for Intravenous Cosentyx Formulation 10/9/2023

First RNA Editing Therapy Nears Clinic as Excitement Mounts

Biospace news - Mon, 10/09/2023 - 02:00
First RNA Editing Therapy Nears Clinic as Excitement Mounts 10/9/2023

Novo Nordisk Boosts Obesity Business with $1B Inversago Buy

Biospace news - Sun, 10/08/2023 - 02:00
Novo Nordisk Boosts Obesity Business with $1B Inversago Buy 8/10/2023

Illumina Lowers Outlook as Business Challenges, Exec Departures Continue

Biospace news - Sun, 10/08/2023 - 02:00
Illumina Lowers Outlook as Business Challenges, Exec Departures Continue 8/10/2023

Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis

Biospace news - Sun, 10/08/2023 - 02:00
Galera Lays Off 70% of Staff After FDA Rejection in Severe Oral Mucositis 8/10/2023

J&J Snags FDA Approval for Second Multiple Myeloma Bispecific Antibody

Biospace news - Sun, 10/08/2023 - 02:00
J&J Snags FDA Approval for Second Multiple Myeloma Bispecific Antibody 8/10/2023